Navigation Links
Shire Receives INTUNIV(TM) Paragraph IV Notice Letter From Anchen
Date:4/27/2010

DUBLIN, April 27, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that it has received a Paragraph IV Notice Letter from Anchen Pharmaceuticals, Inc. ("Anchen") advising of the filing of an Abbreviated New Drug Application ("ANDA") for a generic version of Shire's 1 mg, 2 mg, 3 mg, and 4 mg guanfacine hydrochloride extended release tablets, INTUNIV(TM). Shire had previously reported in March 2010 of the receipt of a Paragraph IV Letter from Teva Pharmaceuticals USA, Inc. and in early April 2010 of a Paragraph IV Letter from Actavis Elizabeth LLC, both regarding ANDAs for generic versions of Shire's 1 mg, 2 mg, 3 mg, and 4 mg guanfacine hydrochloride extended release tablets.

INTUNIV is protected by three FDA Orange Book listed patents: U.S. Patent No. 5,854,290 ("the '290 patent") titled Use of Guanfacine in the Treatment of Behavioral Disorders; U.S. Patent No. 6,287,599 ("the '599 patent") and U.S. Patent No. 6,811,794 ("the '794 patent") both titled Sustained Release Pharmaceutical Dosage Forms with Minimized pH Dependent Dissolution Profiles. The three patents expire in 2015, 2020 and 2022, respectfully.

Shire is currently reviewing the details of Anchen's Paragraph IV Notice Letter which was directed to the '290, '599 and '794 patents.

The Hatch-Waxman exclusivity period for INTUNIV runs until September 2, 2012 therefore, ANDA for generic versions of INTUNIV cannot be approved prior to the end of that exclusivity period.

Under the Hatch-Waxman Act, Shire has 45 days from the receipt of the Notice Letter to determine if it will file a patent infringement suit. If Shire brings suit pursuant to the Hatch Waxman regulations, a stay of approval of up to 30-months will be imposed by the FDA on Anchen's ANDA.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, the Company's results could be materially adversely affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of research, development, approval, reimbursement, manufacturing and commercialization of the Company's Specialty Pharmaceutical and Human Genetic Therapies products, as well as the ability to secure and integrate new products for commercialization and/or development; government regulation of the Company's products; the Company's ability to manufacture its products in sufficient quantities to meet demand; the impact of competitive therapies on the Company's products; the Company's ability to register, maintain and enforce patents and other intellectual property rights relating to its products; the Company's ability to obtain and maintain government and other third-party reimbursement for its products; and other risks and uncertainties detailed from time to time in the Company's filings with the Securities and Exchange Commission.

    For further information please contact:

    Investor         Clea Rosenfeld (Rest of the World)   +44(0)1256-894-160
    Relations
                     Eric Rojas (North America)              +1-781-482-0999
    Media            Jessica Mann (Rest of the World)     +44(0)1256-894-280
                     Matthew Cabrey (North America,
                     Specialty Pharma)                       +1-484-595-8248


'/>"/>
SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Excellent Results in a Transformational Year for Shire; Core Product Sales up 25%
2. Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naive Patients With Type 1 Gaucher Disease
3. Shire Submits Biologics License Application (BLA) for REPLAGAL(R) With the U.S. Food and Drug Administration (FDA)
4. Shire Expands its Award-Winning ADHD Support Resource, ADHDSupport.com, by Launching an ADHD Twitter(TM) Page
5. Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic
6. Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV(TM) (guanfacine) Extended-Release Tablets with Stimulants
7. Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
8. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
9. Shire Continues to Deliver Excellent Growth From Core Products
10. Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30
11. Shire Presents Results of Five Lialda(R) (mesalamine) Analyses at ACG 2009 Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Research and Markets has announced the addition of the ... Trend Indicator):Analysis By Region, By Country (2016-21)" report to their ... Global ... CAGR of 5.33% during 2016-2021 The strong growth is ... demand of digital thermometer. Apart from that, the downfall in the ...
(Date:2/22/2017)... 22, 2017  Allergan plc (NYSE: AGN), a ... a Gold sponsor of the Alzheimer,s Foundation of ... This tour commemorates AFA,s15 years of educating individuals ... programs. The tour will include AFA,s free Concepts ... displays of the AFA Quilt to Remember. ...
(Date:2/22/2017)... February 22, 2017 According to a new market ... In-Line, At-Line), Products and Services (Analyzers, Probes & Sensors), End - User ... MarketsandMarkets, the global market is poised to reach USD 3.30 Billion by ... from 2016 to 2021. Continue Reading ... ...
Breaking Medicine Technology:
(Date:2/22/2017)... , ... February 22, 2017 , ... ... approach, leads to fewer trips the emergency room, fewer hospital admissions, and better ... Journal of Managed Care® (AJMC®) finds. The study can be found here ...
(Date:2/22/2017)... ... February 22, 2017 , ... Sideline Products participated in the World ... TV host Tom Seay and his production crew. Tom Seay’s program “Best of ... the world. Saddle Sidekicks will be featured on April 6, 2017. After the ...
(Date:2/22/2017)... Charleston, WV (PRWEB) , ... February 22, 2017 ... ... has awarded a contract to Quality Insights to help small practices in Delaware, ... Quality Payment Program, established by the Medicare Access and CHIP Reauthorization Act of ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... percent of those report that family members or friends have also commented about ... from hearing loss wear hearing aids. One reason, suggested by 89 percent of ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... military veterans who suffer from combat-related PTSD. , Established in 1977, our organization ... Vietnam-era, the challenges of military returning to civilian life were evident and served ...
Breaking Medicine News(10 mins):